Compare EFR & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFR | PALI |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 305.6M | 359.0M |
| IPO Year | 2003 | 2019 |
| Metric | EFR | PALI |
|---|---|---|
| Price | $10.25 | $1.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $9.80 |
| AVG Volume (30 Days) | 105.9K | ★ 3.3M |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $10.11 | $1.32 |
| 52 Week High | $11.48 | $9.50 |
| Indicator | EFR | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 41.35 | 41.55 |
| Support Level | $10.17 | $1.50 |
| Resistance Level | $10.63 | $2.18 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 19.35 | 59.68 |
Eaton Vance Senior Floating Rate Trust is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income. As a secondary objective, the fund intends to seek capital preservation. Its portfolio of investments consists of Software, Health Care Providers & Services, Machinery, Chemicals, Professional Services, IT Services, Hotels, Restaurants & Leisure, Capital Markets, Specialty Retail, Commercial Services & Supplies, and other areas. The trust invests in below investment grade floating rate loans, which are considered speculative because of the credit risk of their issuers.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.